Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily versus twice-daily aspirin after CABG
2011-002233-19Phase 4Completed
- Sponsor
- Karolinska Institutet
- Start
- Sep 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in coronary arteriosclerosis (3 arms), sponsored by Karolinska Institutet. Primary endpoint: Functional inhibition of the cyclooxygenase pathway. Started Sep 2011; status: completed.
02
Drugs
aspirin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2011-002233-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002233-19.